AcellularSignalApply for access
Ultra RSF-1 · Regenerative signaling factors for licensed healthcare professionals

Cellular signaling. Delivered to the tissue, inside your care plan.

Ultra RSF-1 is the signal stem cells were meant to send: 300 or more proteins and growth factors from all six regions of the placenta, with the cells removed. One small sub-Q injection binds to the tissue and keeps signaling for up to four weeks, so the worn cartilage and inflamed joint get instructions to repair instead of a few weeks of relief. Given in your office or self-administered at home like a peptide. No live cells, no DNA, no freezer.

Apply for accessWatch how it works Physician-ordered. One 1 mL sub-Q injection per treated joint, in-office or at home. Signals up to 28 days. Room temperature.
Ultra RSF-1 vial
What cellular signaling is

The signal, without the cell

Twenty years of stem-cell research reached one conclusion: the cells do not repair the joint. What they secrete does. Ultra RSF is that secreted signal, 300 or more proteins and growth factors from all six regions of the placenta, with the cells removed.

Once delivered, it binds to the collagen and hyaluronic acid in the tissue and keeps signaling for up to four weeks. That signal shifts inflammatory macrophages into repair mode and lowers TNF-α and IL-6 in the synovium. Nothing to engraft, nothing to reject, nothing to wash out in three days.

Ultra RSF 300+ factors AmnionChorionWharton's jelly Cord bloodVillousDecidua
  • Amnion. Anti-inflammatory shield. PGE2 and TSG-6 drive the M1 to M2 macrophage switch.
  • Chorion. Remodeling. VEGF and HGF for new microcirculation.
  • Wharton's jelly. Growth-factor reservoir. TIMP2 protects the matrix from breakdown.
  • Cord blood. Immune modulation and GDF11, the anti-senescence factor.
  • Villous placenta. Nutrient delivery and Annexin A1 to resolve inflammation.
  • Decidua. Regeneration anchor. MCP-1, TGF-β1 and IL-10.
Stem cells and exosomes come from one of these regions. Ultra RSF is drawn from all six.
What the signal does for your practice

Lower pain by 25 to 50 percent. Better outcomes. Patients who stay.

25 to 50%
Lower pain scores in published studies of acellular placental biologics: 6.6 to 2.9 on a 10-point scale in a 21-month spine series, and 22 to 47 percent lower in a one-year low back study.
12 months
Better results that last. In a double-blinded knee OA trial the biologic group was still improving at one year while the cortisone group had faded. Zero adverse events.
Stays with you
The arthritis and disc patient who used to leave for a shot, or pay thousands at a stem cell clinic, now gets the biology from your care plan, keeps coming for everything else you do, and refers the next one.

One small sub-Q injection per joint, given by your staff or self-administered at home just like a peptide. No ultrasound, no procedure room, no referral out.

What every practice already knows

Arthritis is the wearing down of the cartilage between joints. Painkillers are not a long-term solution.

Your patient materials probably say both of those things, and both are right. Whatever your discipline, the tools for an arthritic joint fall into two groups: restore mechanics with manual therapy, decompression, laser, physical therapy or acupuncture, or quiet the symptoms with NSAIDs, cortisone and nerve blocks. What neither group has ever addressed is the cartilage itself: the inflamed synovium, the matrix breaking down, the repair signals that have gone quiet.

So when an arthritic knee or a herniated disc stops holding, the patient goes looking for a cortisone shot, hyaluronic acid or PRP — or pays thousands at a stem cell clinic. Those were the only options that reached the biology. Each has a ceiling, most required a procedure room and an ultrasound, and the patient who left for one often never came back.

And you watched the stem cell wave roll through your field — the seminars, the big-ticket packages, the mixed results, the FDA letters. The instinct behind it was right: give the joint biology, not just mechanics or symptom control. The execution was the problem.

In a double-blinded trial of severe knee OA, the steroid and the placental biologic gave the same relief at 6 weeks. By 12 months the steroid had worn off. The biologic group was still improving, with zero adverse events.

The add-on your practice has been missing

Keep doing what you do. Add the one thing you could not.

Ultra RSF does not replace anything in your practice. It adds the layer your current methods have not been able to deliver: regenerative signaling that stays in the joint for weeks, from your own care plan, without a procedure room or a referral out.

What you already do

Manual therapy, decompression, Class IV laser, acupuncture, physical therapy and rehab, peptide and hormone protocols, IV therapy, pain procedures, aesthetics. All of it stays in the plan.

What you could not do for long

Change the environment inside the joint and keep it changed. Cortisone fades by a year, HA underperforms, PRP depends on the patient's own blood, and cells and exosomes wash out in days and need a freezer.

What Ultra RSF adds

Acellular placental signaling factors, delivered as one sub-Q injection, that shift the joint from inflammatory to reparative and keep signaling for weeks. Your patient, your plan, your practice.

The result is a care plan that works on both halves of the problem at once: your protocol on the mechanics and symptoms, Ultra RSF on the biology. Pain comes down, results hold, and the patient who used to leave for an injection stays on your schedule for the next twelve months of care.

Built for your kind of practice

One signal. Nine ways it fits the practice you already run.

The biology is the same in every setting. What changes is who orders it, who gives the injection and how it sits on your menu. Find your practice below.

Medical doctors (MD / DO)

Primary care, pain, orthopedics, sports medicine, internal medicine

You already own the injection conversation. The patient with the arthritic knee or the failing disc asks you about cortisone, hyaluronic acid or PRP, and you know the ceiling on each: the steroid matches the biologic at 6 weeks and is gone by 12 months, HA lost to amniotic allograft in a 200-patient trial, and PRP depends on the blood the patient walks in with. Ultra RSF-1 gives you a fourth option that you order yourself, that needs no ultrasound or procedure room, and that in the published class kept improving through a year. It also keeps the patient who was about to spend thousands at a stem cell clinic inside your care.

  • Who ordersYou order it under your own license.
  • Who gives itYour MA or nurse gives the sub-Q injection in the office, or the patient does it at home.
  • How it is pricedCash add-on alongside your existing injection menu. No insurance billing involved.

Nurse practitioners

Independent and collaborative practices, primary care, aesthetics, hormone and weight clinics

Many of the practices that run peptides, hormones and GLP-1 protocols are NP-led, and those patients already self-inject. Ultra RSF-1 is the same 1 mL sub-Q technique with a different purpose: a regenerative signal for the joint, tendon or disc that is slowing them down. In full-practice-authority states you order it directly. Where you work under a collaborative agreement, the collaborating physician or a Regen MDs physician signs the order. Either way the vial sits in a cabinet, not a freezer, and nothing about it changes your scope.

  • Who ordersYou order it where your state grants prescriptive authority; otherwise your collaborating physician or Regen MDs.
  • Who gives itYou or your staff give it in the office, or the patient self-administers like a peptide.
  • How it is pricedCash add-on, priced like your peptide and hormone protocols.

Physician assistants

Orthopedic, pain management, sports medicine and primary care teams

PAs carry most of the follow-up on joint patients: the six-week recheck after the steroid, the second HA series, the PRP that did not take. Ultra RSF-1 gives that visit something new to offer. It is standardized vial to vial, with 300 or more factors from six placental regions, so you are not relying on the patient's platelet count. Order it under your practice agreement, give it sub-Q in the room, score the patient again at four to six weeks, and add a second vial if the signal is worth extending.

  • Who ordersOrdered under your supervising physician and practice agreement, or by a Regen MDs physician.
  • Who gives itYou give the sub-Q injection in clinic, or the patient does at home.
  • How it is pricedCash add-on to the orthopedic or pain practice's self-pay menu.

Chiropractors

Disc, arthritis, sports and chronic spine patients

Adjustment, decompression and laser restore motion and take pressure off the nervous system. What no chiropractic tool has reached is the cartilage itself, so the patient who stops holding leaves for a shot and often does not come back. Ultra RSF-1 fixes that without asking you to inject. A Regen MDs physician reviews the case and orders the vial, the patient gives it to themselves at home like a peptide, and your clinic runs the evaluation, the laser and rehab plan, and the follow-up. The biology comes from your care plan, and the patient stays on your schedule.

  • Who ordersA Regen MDs physician reviews the case and orders the vial.
  • Who gives itThe patient self-administers at home after a 30-second walkthrough from your staff.
  • How it is pricedCash add-on, like laser packages and orthotics. Nothing touches your insurance billing.

Acupuncturists

Chronic pain, inflammation, arthritis and recovery patients

Your patients come for the inflammatory and pain-modulating effect of treatment, and most of the chronic ones have a joint, tendon or disc that flares between sessions. Ultra RSF-1 works on the same problem from the inside: it shifts macrophages from inflammatory to repair mode and lowers TNF-α and IL-6 in the synovium, and it keeps signaling for up to four weeks, which is roughly a course of treatment. It is ordered by a physician and self-administered at home, so it adds a regenerative layer to your plan without changing what you do in the room.

  • Who ordersA Regen MDs physician reviews the case and orders the vial.
  • Who gives itThe patient self-administers at home; your clinic coordinates timing with the treatment course.
  • How it is pricedCash add-on priced alongside your treatment packages.

Medical spas

Aesthetic, longevity, peptide and IV clients under a medical director

You already run a cash-pay menu with injectables, peptides and IV therapy, and your clients ask about recovery, joints and longevity as often as skin. Ultra RSF-1 is a regenerative line that fits the operation you have: the medical director orders, an RN or NP gives the sub-Q injection, and the vial stores at room temperature for 24 months, so no stock is lost to a thawed freezer. Athletes, active clients over 45 and anyone who has priced a stem cell package are the natural first patients.

  • Who ordersYour medical director orders it.
  • Who gives itYour RN, NP or PA gives the sub-Q injection during the visit.
  • How it is pricedCash service alongside peptides and IV therapy. Room temperature, 24-month shelf life.

Physical therapy clinics

Post-injury, osteoarthritis, tendinopathy and plateaued rehab patients

The trials behind this page score outcomes with KOOS and Lysholm, the same instruments you already use, and the biologic group kept improving on them through 12 months. The clinical picture that matters to you is the plateau: the knee that stops progressing at week six no matter how well the program is built. Load and motion tell the tissue what to become; Ultra RSF-1 supplies the growth factors and signaling proteins that tell it how to rebuild. The patient self-administers at home, and your plan of care stays exactly as you wrote it.

  • Who ordersA Regen MDs physician reviews the case and orders the vial.
  • Who gives itThe patient self-administers at home; you track it in your outcome scores.
  • How it is pricedCash add-on to self-pay and wellness rehab programs.

Functional and regenerative medicine

Practices already using PRP, peptides, exosomes or cellular products

You know the field's problems from the inside: fewer than 5 percent of injected cells survive 48 hours in an inflamed joint, exosomes wash out in one to three days, PRP varies with the patient, and cells and exosomes need a minus-80 freezer. Ultra RSF-1 is the acellular answer to each. It is a Section 361 tissue product, standardized vial to vial, drawn from all six placental regions rather than one, binds to the tissue's own collagen and hyaluronic acid, and signals for up to 28 days. It stacks into the peptide, hormone and IV protocols you already run.

  • Who ordersYou or your medical director order it.
  • Who gives itGiven in the office or self-administered at home, inside your existing protocol.
  • How it is pricedReplaces or sits beside your current regenerative offer. No freezer, no thaw, no wasted vials.

Wellness clinics and other licensed facilities

IV therapy, hormone, weight, longevity and performance clinics

Your members come for the long game: energy, recovery, healthspan. Ultra RSF-1 gives the clinic a regenerative signaling program with the same operational profile as what you already offer. It is physician-ordered, sub-Q, room temperature and cash-pay. Joints and recovery are the clearest use, with published results. The same signaling is also being studied in neurological and cardiac conditions; that evidence is early, and it is listed in the research section so your medical director can read it directly.

  • Who ordersYour medical director, or a Regen MDs physician, orders it.
  • Who gives itYour licensed staff give it, or the member self-administers at home.
  • How it is pricedCash membership or package add-on. Use is subject to your state's scope of practice rules.
Two short videos

Not stem cells. Not exosomes. Watch what Ultra RSF is instead.

Want to read the research yourself? Every study is listed below, with the full clinical slide deck.

What your patients have tried

Every injection they have had, and where Ultra RSF goes further

Some of these you may already offer. Each has a known ceiling in the literature. Ultra RSF is the first regenerative option in this class that fits inside any licensed practice: no cells, no freezer, no procedure room.

Your patients triedWhy it fell shortUltra RSF, in your practice
CorticosteroidMatches the biologic at 6 weeks, then fades. No improvement at 12 months in the RCT.Placental biologic still improving at 12 months. Zero adverse events.
Hyaluronic acidBeaten by amniotic allograft on pain, function and symptoms at 3 and 6 months in a 200-patient RCT.Same product class that beat HA and saline.
PRPDepends on the patient's own blood. Trial patients had already failed PRP, steroids and HA before the placental biologic worked.Donor-derived and standardized. 300+ proteins and growth factors, the same vial to vial.
PeptidesSame easy sub-Q self-injection, but the signal lasts minutes to hours and is not joint-specific.Same self-administered technique. Signal designed to persist in the joint for weeks.
Stem cellsUnder 5 percent of cells survive 48 hours in an inflamed joint. Foreign DNA, immune risk, minus-80 freezer.Zero cells. The signals the cells were making, with none of the cells.
ExosomesWash out of the joint in 1 to 3 days. Volatile RNA cargo. Freezer required.Binds to the tissue's own collagen and hyaluronic acid. Signals stay up to 28 days.
How it was deliveredIntra-articular or epidural, under ultrasound or fluoroscopy, by an injecting provider in a procedure room. For non-injecting practices, a referral out.One 1 mL sub-Q injection per joint, 30 seconds. Given by your staff or self-administered at home just like a peptide, inside your care plan.
StorageCryofreezing for cells and exosomes. Wasted vials.Room temperature. 24-month shelf life.
Peptides minutes to hours Stem cells, exosomes 1 to 7 days, then cleared Ultra RSF binds to tissue · signals up to 28 days Day 0 Week 1 Week 2 Week 3 Week 4
How long the signal stays at the tissue. Bar lengths are drawn to the four-week scale.
Your protocol plus RSF

Whatever you already treat the joint with, RSF is the next layer.

Laser gives the cell energy. Manual therapy, decompression and rehab give it motion and load. Acupuncture, peptides and IV protocols support the terrain. Ultra RSF gives the cell instructions, the growth factors and signaling proteins that tell it what to rebuild. It fits the same four-to-six-week cadence most joint protocols already run, in a chiropractic office, a PT clinic, a med spa or a regenerative medicine practice.

Week 0

Start

Evaluate · treat · dose

Baseline pain and function scores. First Ultra RSF vial for the treated joint. Your usual modalities continue.

Weeks 1 to 4

Signal

Your protocol 2 to 3× weekly

RSF keeps signaling in the joint for up to four weeks while laser, manual care, rehab or your regenerative protocol continue on their normal cadence.

Week 4 to 6

Reassess

Score · second vial if indicated

Repeat scores. A second vial for the joint if the patient is progressing and the provider wants to extend the signal.

The evidence

Published results: pain down, function up, and it holds

12 months
Still improving in severe knee OA while corticosteroid had faded. 81 patients, double-blinded, zero adverse events.
200 patients
Amniotic allograft beat hyaluronic acid and saline on KOOS pain, function and symptoms at 3 and 6 months.
56% less pain
Spine pain fell from 6.6 to 2.9 out of 10 and held at a mean 21 months after a single placental injection in patients who had failed everything else.

Repeat dosing works too. Patients who failed HA or saline and then received the placental biologic improved as much as first-line patients, through 12 months.

Read the research

Every study behind this page, and the full clinical deck

Open any group below. Each entry links to the original paper. The trials studied acellular placental and amniotic biologics as a product class; Ultra RSF is a Section 361 tissue product in that class.

Osteoarthritis and joints8 studies
  • Amniotic tissue injections vs. corticosteroid for severe knee OAJAAOS Global Research & Reviews, 2025 · Double-blinded RCT, N=81, KL grade 3–4

    Both groups improved at 6 weeks. The amnion group kept improving through 12 months and met MCID on Lysholm, KOOS ADL and KOOS Pain. Zero adverse events in the amnion arm.

    Read the study ↗
  • Allogenic amniotic tissue for knee and hip OA: review of three clinical trialsPharmaceuticals, 2022 · Includes a 200-patient RCT

    Amniotic suspension allograft beat hyaluronic acid and saline at 3 and 6 months on KOOS pain, ADL and symptoms, with a higher OMERACT-OARSI responder rate. No major adverse events.

    Read the study ↗
  • Amniotic suspension allograft crossover study for knee OAArthroscopy, 2023 · Crossover RCT, 12-month follow-up

    Patients who failed HA or saline and crossed over to amniotic allograft improved as much as first-line patients. Gains held through 12 months. No immunologic events.

    Read the study ↗
  • Amniotic suspension allograft for knee OA: editorial on the Natali pilotPharmaceuticals, 2022 · Editorial on a 25-patient prospective pilot

    IKDC and VAS improved at 3, 6 and 12 months with no severe adverse events. Patients had already failed NSAIDs, physical therapy, cortisone, HA or PRP. Notes that similarly named products can differ in composition.

    Read the study ↗
  • Decellularized extracellular matrix for cartilage repair in OA: meta-analysisJournal of Orthopaedic Surgery and Research, 2025 · 10 preclinical studies

    Significant cartilage repair on ICRS score (WMD 2.45). Animal models, so this supports mechanism rather than patient outcomes.

    Read the study ↗
  • Acellular placental extract in post-traumatic OAOsteoarthritis and Cartilage Open, 2025 · Preclinical

    OARSI score 1.8 vs 9.17 for saline. Inhibited MMP activity and preserved cartilage matrix in explants.

    Read the study ↗
  • Placental MSC secretome repairs meniscus injury by activating meniscus progenitor cellsStem Cell Research & Therapy, 2025 · Mouse model and in vitro

    Improved gait and rotarod performance, reduced TNF-α, increased cartilage matrix and collagen. Identifies TIMP1, TIMP2, IGF-1 and VEGFA in the secretome. Small pilot, mechanism-level.

    Read the study ↗
  • Active clinical trials in acellular amniotic tissue for knee OAClinicalTrials.gov · NCT04201743, NCT06704893, NCT04636229 (Phase III, N=474)

    Registered randomized trials now recruiting. No results yet; listed so you can follow them.

    View on ClinicalTrials.gov ↗
Spine and pain3 studies
  • Epidural amnion and umbilical cord particulate for lumbar radiculopathyFrontiers in Pain Research, 2024 · Consecutive clinical series, mean 21-month follow-up

    Pain 6.6 at baseline, 2.0 at 6 months, 2.9 at last follow-up after a single injection. All patients had failed conventional care.

    Read the study ↗
  • Epidural amniotic fluid injection for low back painInterventional Pain Medicine, 2025 · Clinical study, 1-year follow-up

    Stenosis: low back VAS 6.8 to 5.3, ODI 46 to 33. Herniated disc: MCID reached in 65 to 79 percent. Reduced pain medication use.

    Read the study ↗
  • Amniotic fluid exosomes alleviate neuropathic pain via microglial modulationFASEB Journal, 2025 · Preclinical

    Restored microglial balance and reduced pain behaviors in a nerve injury model.

    Read the study ↗
Mechanism: why the signal works without the cell8 studies
  • Stem cell secretome, regeneration and clinical translation: a narrative reviewAnnals of Translational Medicine, 2021 · Wake Forest orthopedics

    The foundational argument that paracrine signaling, not cell engraftment, drives the effect. Covers dosing, delivery and the anti-inflammatory action on synovial cells.

    Read the study ↗
  • Mesenchymal stem cells: time to change the nameStem Cells Translational Medicine, 2017 · Caplan

    Proposes renaming MSCs to reflect that their value is in what they secrete.

    Read the study ↗
  • MSC-conditioned medium reduces disease severity in inflammatory arthritisScientific Reports, 2017 · Murine model

    Lower leukocyte accumulation in the joint synovium at day 3 and higher regulatory T-cell markers near the arthritic joint.

    Read the study ↗
  • Exosomes from adipose-derived stem cells suppress inflammation in knee OA synovial fibroblastsMolecular Medicine Reports, 2020 · In vitro

    Down-regulated IL-6, NF-κB and TNF-α, up-regulated IL-10 in activated synovial fibroblasts.

    Read the study ↗
  • TSG-6 from placental MSCs induces M2 macrophage polarizationScientific Reports, 2017

    The pathway behind the M1-to-M2 shift described on this page.

    Read the study ↗
  • Decellularized ECM immunogenicity and scaffold retentionMaterials, 2023 and Regenerative Biomaterials, 2023

    Properly decellularized matrices are minimally immunogenic and stay bound to host tissue.

    Read the study ↗
  • Umbilical cord plasma proteins revitalize hippocampal function in aged miceNature, 2017 · Castellano et al.

    The TIMP2 finding behind the cord blood and Wharton's jelly section.

    Read the study ↗
  • Wharton's jelly as a reservoir of peptide growth factorsPlacenta, 2005

    Documents the growth-factor content of Wharton's jelly.

    Read the study ↗
Wound healing and inflammatory conditions4 studies
  • Placental-derived biomaterials for wound healing: review of RCTsBioengineering, 2023

    Placental scaffolds healed 75 percent of wounds vs 30 percent for standard care; diabetic foot ulcers 92 percent vs 8 percent.

    Read the study ↗
  • Amniotic membrane transplantation for wound healing: comprehensive reviewStem Cell Reviews and Reports, 2025

    Faster closure, less scarring, lower infection rates. Explains the anti-scarring mechanism.

    Read the study ↗
  • Human amniotic membrane cells suppress rheumatoid arthritis inflammationPubMed, 2014 · Preclinical, four autoimmune models

    Generated regulatory T cells and suppressed collagen-induced arthritis.

    Read the study ↗
  • Placenta and placental derivatives in regenerative therapiesStem Cells International, 2018 · Review

    Overview of placental derivatives across autoimmune, endocrine and nervous system conditions.

    Read the study ↗
Neurological and cardiac5 studies
  • Secretome as neuropathology-targeted intervention for Parkinson's diseaseRegenerative Therapy, 2022 · Review

    Secretome targets five Parkinson's pathways including neurotrophin deficiency and neuroinflammation.

    Read the study ↗
  • Amniotic fluid stem cell exosomes protect neurons from amyloid-beta toxicityInternational Journal of Molecular Sciences, 2022 · In vitro

    Reduced microglial inflammation and neuronal apoptosis in an Alzheimer's model.

    Read the study ↗
  • Placenta-derived cells for acute brain injuryCell Transplantation, 2018 · Systematic review

    Anti-inflammation, anti-apoptosis, angiogenesis and neurogenesis in TBI and stroke, with a table of registered trials.

    Read the study ↗
  • Secretome as a tool to treat neurological conditions: are we ready?International Journal of Molecular Sciences, 2023 · Review

    Consolidates the cell-free evidence in neurology and names the remaining gaps.

    Read the study ↗
  • MSC secretome for cardiac regenerationPMC, 2025 · Review

    Anti-apoptosis, anti-fibrosis and angiogenesis without cell transplantation.

    Read the study ↗
In your practice

How it works in your practice

Ultra RSF asks nothing new of your clinic. If you inject, your staff gives it during the visit. If your license does not include injecting, the patient does it at home, like a peptide. No new equipment, no new staff, and the patient stays with you.

Ultra RSF-PRO vial with insulin syringe

In-office, or at home like a peptide

The vial is ordered under a physician's license: yours, or a Regen MDs physician who reviews the case if you do not prescribe. It is one small 1 mL sub-Q injection. Your staff can give it in the office, or the patient gives it to themselves at home exactly the way peptide patients already do, with a 30-second walkthrough. Your practice runs the evaluation, the protocol and the follow-up.

Sits in a cabinet

Room temperature, two-year shelf life. Reconstitute with 1 mL sterile water. No freezer, no thaw, nothing expires while you build your patient list.

Cash add-on, like peptides and laser

Ultra RSF is sold outside insurance, the same way peptide protocols, IV therapy, laser packages and aesthetic services are. The payment plans you already offer self-pay patients apply. Nothing about it touches your insurance billing.

The three-month arc your patient follows

Month 1

Repair

Calm · seal · protect

Inflammation settles. The joint stops flaring between visits.

Month 2

Rebuild

Supply · construct · perfuse

New matrix is laid down. Collagen and microcirculation are supported.

Month 3

Remodel

Organize · mature · hold

Collagen types balance out. A maintenance rhythm is set with your care plan.

From patients

Hear it from people who were where your patients are

Short video testimonials from Regen MDs patients: spinal disc issues, sports and rotator cuff, osteoarthritis. Tap a card to watch on YouTube.

Beyond joints: the same signaling, other conditions

Individual patient experiences. Results vary and these clips are not a guarantee of outcome.

What your patients would read

A handout in your practice's voice

Written the way a patient-facing condition page is written, ready to adapt for your website or the front desk.

Patient handout · draft

Arthritis got you down? There is now something for the cartilage itself.

For years, the care we provide here has helped arthritis and joint patients move better and hurt less. What we could never treat directly was the worn cartilage inside the joint.

Ultra RSF is a regenerative signaling treatment made from donated placental tissue, processed so it contains no living cells. What remains are the natural proteins the body uses to calm inflammation and support repair. It is ordered by a physician and given as one small injection under the skin, either here in our office or by you at home the same way peptide or insulin patients do, alongside your regular care plan here.

In a randomized trial of severe knee arthritis, this class of treatment outperformed a cortisone shot at one year, with no adverse events reported. It is not a cure, and results vary from person to person. In published studies of this class of treatment, pain scores fell by a quarter to a half and the improvement held for a year or longer. Results vary from person to person.

If you have arthritis, a disc problem or a joint that is not responding the way it used to, contact us today for a complimentary consultation to find out whether Ultra RSF may be right for you. Call us at [clinic phone] or request an appointment online.

Apply for access

Tell us about your practice and your patients

A short application. We read every one and reply personally. Use the vial formats below to size your first batch: one vial treats one joint or area.

Ultra RSF-1 two-dose and Ultra RSF-PRO four-dose vials
Ultra RSF-PROOne vial is one full dose: a complete treatment for one joint or area. Labeled 4 dose units. Reconstitute with 1 mL sterile water and inject as one sub-Q injection.
Ultra RSF-1One vial is a half dose. Labeled 2 dose units. Same 1 mL reconstitution, for a smaller area, a lighter first exposure or a booster.
One injection per areaOne vial, one area, one sub-Q injection. Two knees means two vials. No splitting or drawing up partial vials.
About you
About your patients
About RSF and your practice

Use is subject to your state board's scope of practice. We confirm the delivery route with you before anything ships.

Sources. 12-month steroid comparison: amniotic tissue vs. corticosteroid RCT, N=81, JAAOS Glob Res Rev 2025, PMC11723680. 200-patient comparison with HA and saline: Gupta, Pharmaceuticals 2022, PMC9031613. Repeat dosing: ASA crossover RCT, Arthroscopy 2023. 25 to 50 percent pain reduction: epidural amnion and cord series (6.6 to 2.9), Front Pain Res 2024, and epidural amniotic fluid low back study (22 to 47 percent), Interv Pain Med 2025, PMC12166700. 21-month spine series: Front Pain Res 2024, PMC10839066. Prior PRP failure in trial patients: Gupta editorial on Natali 2022, PMC9599686. Synovial TNF-α and IL-6 mechanism: Gwam et al., Ann Transl Med 2021. Placental region factors, cell survival, washout, ECM binding and storage: Life Force Lab clinical slidedoc. Vial formats, 1 mL reconstitution, routes, 300+ factors, signal duration and the three-month arc: regenmds.com and lifeforcelab.com. One-vial-per-area dosing: Life Force Lab clinical guidance.

The trials cited studied acellular placental and amniotic biologics as a product class. Ultra RSF is a Section 361 human tissue product in that class, exempt from FDA premarket review and not intended to diagnose, treat, cure or prevent any disease.